Log in
NYSE:ABT

Abbott Laboratories Stock Forecast, Price & News

$106.41
-1.20 (-1.12 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$105.63
Now: $106.41
$108.40
50-Day Range
$105.00
MA: $109.59
$114.42
52-Week Range
$61.61
Now: $106.41
$115.14
Volume6.22 million shs
Average Volume6.94 million shs
Market Capitalization$188.60 billion
P/E Ratio56.30
Dividend Yield1.34%
Beta0.9
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.
Read More
Abbott Laboratories logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.7Dividend Strength: 3.3Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.22 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP00282410
CIK1800
Phone224-667-6100
Employees107,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.90 billion
Cash Flow$4.79 per share
Book Value$17.83 per share

Profitability

Net Income$3.69 billion

Miscellaneous

Outstanding Shares1,772,362,000
Market Cap$188.60 billion
Next Earnings Date1/27/2021 (Estimated)
OptionableOptionable
$106.41
-1.20 (-1.12 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

How has Abbott Laboratories' stock price been impacted by COVID-19?

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ABT shares have increased by 36.3% and is now trading at $106.41.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Abbott Laboratories?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Abbott Laboratories
.

What stocks does MarketBeat like better than Abbott Laboratories?

Wall Street analysts have given Abbott Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abbott Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Wednesday, January 27th 2021.
View our earnings forecast for Abbott Laboratories
.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) posted its quarterly earnings data on Wednesday, October, 21st. The healthcare product maker reported $0.98 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.90 by $0.08. The healthcare product maker had revenue of $8.85 billion for the quarter, compared to the consensus estimate of $8.53 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 18.19%. The firm's revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.84 earnings per share.
View Abbott Laboratories' earnings history
.

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories announced a quarterly dividend on Thursday, September 17th. Stockholders of record on Thursday, October 15th will be paid a dividend of $0.36 per share on Monday, November 16th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 1.35%. The ex-dividend date of this dividend is Wednesday, October 14th.
View Abbott Laboratories' dividend history
.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, October, 21st. The company provided earnings per share (EPS) guidance of 3.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.32.

What price target have analysts set for ABT?

18 brokerages have issued 12 month price objectives for Abbott Laboratories' shares. Their forecasts range from $94.00 to $130.00. On average, they anticipate Abbott Laboratories' stock price to reach $115.38 in the next twelve months. This suggests a possible upside of 8.4% from the stock's current price.
View analysts' price targets for Abbott Laboratories
.

Who are some of Abbott Laboratories' key competitors?

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T), Pfizer (PFE), The Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), The Home Depot (HD) and Verizon Communications (VZ).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the following people:
  • Mr. Miles D. White M.B.A., Exec. Chairman (Age 65, Pay $6.97M)
  • Mr. Robert B. Ford, CEO, Pres, COO & Director (Age 46, Pay $2.63M)
  • Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 41, Pay $1.67M)
  • Ms. Lisa D. Earnhardt, Exec. VP of Medical Devices (Age 50, Pay $1.33M)
  • Mr. Robert E. Funck Jr., Exec. VP of Fin. & CFO (Age 59)
  • Mr. Scott Michael Leinenweber, VP of Investor Relations, Licensing & Acquisitions (Age 48)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • James E. Young, VP and Chief Ethics & Compliance Officer
  • Ms. Melissa Brotz, VP of Public Affairs & Corp. Marketing
  • Ms. Elaine R. Leavenworth, Sr. VP and Chief Marketing & External Affairs Officer (Age 61)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.63%), State Street Corp (4.16%), Massachusetts Financial Services Co. MA (1.45%), Morgan Stanley (1.43%), Charles Schwab Investment Management Inc. (0.62%) and Nuveen Asset Management LLC (0.53%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John F Ginascol, John G Stratton, John M Capek, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, Roxanne S Austin, Sally E Blount, Sharon J Bracken and Stephen R Fussell.
View institutional ownership trends for Abbott Laboratories
.

Which institutional investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Assenagon Asset Management S.A., Coho Partners Ltd., State Street Corp, Diamond Hill Capital Management Inc., Nuveen Asset Management LLC, State of Tennessee Treasury Department, and KBC Group NV. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Jared Watkin, John F Ginascol, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, and Roxanne S Austin.
View insider buying and selling activity for Abbott Laboratories
.

Which institutional investors are buying Abbott Laboratories stock?

ABT stock was purchased by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Massachusetts Financial Services Co. MA, Menora Mivtachim Holdings LTD., Morgan Stanley, DekaBank Deutsche Girozentrale, Railway Pension Investments Ltd, AustralianSuper Pty Ltd, and Bradley Foster & Sargent Inc. CT. Company insiders that have bought Abbott Laboratories stock in the last two years include John G Stratton, and Randel William Woodgrift.
View insider buying and selling activity for Abbott Laboratories
.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $106.41.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $188.60 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 107,000 workers across the globe.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is www.abbott.com.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.

This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.